Takeda Pharmaceuticals USA, Inc.
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 4 disclosed transactions, Takeda Pharmaceuticals USA, Inc. concentrates its licensing activity in Neurology, Oncology, and RareDisease. Takeda Pharmaceuticals USA, Inc. pays a 1.50x premium over market median. Their most common deal structure is Option, with an average disclosed value of $2.1B. Most recent activity: 2024.
Pipeline coverage & gaps
Takeda Pharmaceuticals USA, Inc. has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| OptionPrimary | 2 | $100M | $2.1B |
| CollaborationPrimary | 2 | $173M | $2.1B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | ACI-24.060 | AC Immune SA | alzheimer's disease and alzheimer's disease in down syndrome | phase_2 | $100M | $2.2B |
| 2024 | ACI-24.060 | AC Immune SA | alzheimer's disease and alzheimer's disease in Down syndrome | phase_2 | $100M | $2.1B |
| 2024 | rusfertide | Protagonist Therapeutics, Inc. | polycythemia vera | phase_3 | $300M | $630M |
| 2021 | in-vivo gene therapy programs | Poseida Therapeutics, Inc. | hemophilia a | preclinical | $45M | $3.6B |
How this is computed
For each Takeda Pharmaceuticals USA, Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 3.818, clamped to [0.7, 1.5].